CEMI - Chembio Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Chembio Diagnostics, Inc.

3661 Horseblock Road
Medford, NY 11763
United States
631-924-1135
http://chembio.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees295

Key Executives

NameTitlePayExercisedYear Born
Mr. John J. Sperzel IIIPres, CEO & Director506.1kN/A1964
Mr. Neil A. GoldmanExec. VP & CFO347.4kN/A1968
Mr. Javan EsfandiariChief Science & Technology Officer and Exec. VP437.65kN/A1967
Mr. David A. GyorkeSr. VP & COON/AN/A1960
Dr. Christine M. RousseauVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Corporate Governance

Chembio Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.